drugset / Trial / NCT02968394

Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions

NCT02968394

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to systemic reactions.

Timeline

Start
2014-03
Primary completion
2017-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody

Indications